RedHill Biopharma Ltd – ADR Stock Rises After Positive Phase III Results of BEKINDA Treatment

Israel-based biopharmaceutical company RedHill Biopharma Ltd – ADR (NASDAQ:$RDHL) saw its stocks rise after the company’s release of the results from its Phase III clinical trial named GUARD. GUARD tested the performance of using RHB-102 (labelled BEKINDA) to treat patients with acute gastroenteritis and gastritis, and yielded positive results.

Robert Silverman, Lead Investigator of GUARD, commented on the positive phase III trial:

“If approved by FDA, BEKINDA® may become the new standard of care helping us treat patients quickly and effectively in both the emergency and outpatient settings,” he said.  Acute gastroenteritis and gastritis is a relatively common illness that affects almost 179 million people in the US each year, he added.

Healthcare, healthcare investing, investing in healthcare, healthcare investments, investing in healthcare mutual funds, investor healthcare, healthcare stocks to invest in, invest in healthcare, healthcare investor, healthcare investment, healthcare stocks today, healthcare investors, healthcare investment bank, healthcare mutual funds, healthcare savings, medicine stocks, healthcare industry companies, medical stocks, healthcare stock, health sector stocks, healthcare stock market, health services stocks, investing in pharmaceutical companies, pharmaceutical investment, investing in pharmaceutical stocks, pharmaceutical companies to invest in, best pharmaceutical companies to invest in, pharmaceutical companies stocks, up and coming pharmaceutical companies, drug company stocks, pharmaceutical companies to invest in 2017, pharmaceutical stock, pharmaceutical stocks, pharmaceutical mutual funds, pharmaceutical penny stocks, pharma stocks, pharmaceutical companies, top pharmaceutical stocks, pharmaceutical stocks list, pharmaceutical stocks to watch, best drug company stocks, drug stocks, new pharmaceutical stocks, pharma sector analysis
Source: Simply.wall.st.com

The announcement can change RedHill’s status as a highly volatile share; the company’s market capitalization is currently just over $150 million and many did not expect it to have any products to sell on markets — much less make any large revenues — any time soon. If the GUARD study continues to deliver positive, safe, and effective data for its final phase of study, the drug could be on its way to gaining marketing approval from the FDA.

More Products Coming?

While investors may be clamouring for RedHill shares due to the potential that BEKINDA has to be the company’s first commercial product, other drugs such as RHB-104 and RHB-105 are also in its Phase III study and carries high potential to be on the market as well.

RHB-104 is a combination of antibiotics that is taken orally. The drug was developed to treat Crohn’s disease with the hypothesis that the illness is caused by Mycobacterium avium subspecies paratuberculosis (MAP). While there are still several things to do before the hypothesis can be confirmed — including a partner study with Quest Diagnostics to find MAP in whole blood — if Redhill could find a cure for a life-changing and painful illness such as Crohn’s, it could mean massive success and recognition for the company.

RHB-105 is a drug developed to treat gastric ulcers. Current treatment for the illness is only effective in only a third of those who has it, but with the RHB-105 showing successful results from its first Phase III study, this could very well change. Like BEKINDA and RHB-104, if the final study shows the same success and effectiveness and gains marketing approval from the FDA, the valuation of Redhill could increase dramatically.

Featured Image: koreabizwire.com

About the author: Grace is currently studying at UBC to achieve her BA in Computer Science. She is due to graduate in 2020. As a content creator, Grace has written financial analysis, stock market news, and informational investing articles. She also worked as an editor with her university publication 'UBC Undergraduate Journal of Art History'.